Ferrante M, D'Haens G, Jairath V, Danese S, et al. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study. Lancet 2024 Nov 21:S0140-6736(24)01762-8. doi: 10.1016/S0140-6736(24)01762.
PMID: 39581202